Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome
- 25 June 2009
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 113 (26), 6533-6540
- https://doi.org/10.1182/blood-2009-01-176032
Abstract
Phase 1 testing of ezatiostat, a glutathione S-transferase P1-1 inhibitor, for the treatment of myelodysplastic syndrome was conducted in a multidose-escalation study. Patients received 10 dose levels (200, 400, 1000, 1400, 2000, 2400, 3000, 4000, 5000, and 6000 mg) of ezatiostat tablets in divided doses on days 1 to 7 of a 21-day cycle for a maximum of 8 cycles. The safety and pharmacokinetics of ezatiostat were evaluated. Forty-five patients with low to intermediate-2 International Prognostic Scoring System risk myelodysplastic syndrome were enrolled. No dose-limiting toxicities were observed. The most common grade 1 or 2, respectively, treatment-related adverse events were nonhematologic: nausea (56%, 9%), diarrhea (36%, 7%), vomiting (24%, 7%), abdominal pain (9%, 0%), constipation (4%, 9%), anorexia (3%, 7%), and dyspepsia (3%, 7%). Concentration of the primary active metabolite, TLK236, increased proportionate to ezatiostat dosage. Seventeen hematologic improvement (HI) responses by International Working Group criteria were observed at dose levels of 200 to 6000 mg/day with 11 HI responses at doses of 4000 to 6000 mg/day. HI responses occurred in all lineages including 3 bilineage and 1 complete cytogenetic response. Decreased number of red blood cell and platelet transfusions and in some cases transfusion independence were attained. Extended dose schedules of ezatiostat tablets are under investigation. This study was registered at http://www.clinicaltrials.gov as NCT00280631.Keywords
This publication has 19 references indexed in Scilit:
- Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions–a reviewBritish Journal of Haematology, 2008
- Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaBlood, 2006
- Once-weekly dosing of recombinant human erythropoietin alpha in patients with myelodysplastic syndromes unresponsive to conventional dosingAnnals Of Oncology, 2004
- Cytogenetics in acute leukemiaBlood Reviews, 2003
- Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group BJournal of Clinical Oncology, 2002
- Thalidomide for the treatment of patients with myelodysplastic syndromesLeukemia, 2002
- Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS‐related acute myeloid leukaemiaBritish Journal of Haematology, 1996
- The effect of 1‐hydroxyvitamin D3 for prolongation of leukemic transformation‐free survival in myelodysplastic syndromesAmerican Journal of Hematology, 1991
- Treatment of myelodysplastic syndrome with 1.25‐dihydroxy‐vitamin D3American Journal of Hematology, 1986
- Chronic myelodysplastic syndrome: short survival with or without evolution to acute leukaemiaBritish Journal of Haematology, 1983